<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2489">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397562</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-089-4</org_study_id>
    <nct_id>NCT04397562</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19</brief_title>
  <acronym>CORONA</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective: to study the efficacy and safety of levilimab in subjects with severe&#xD;
      COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is multicenter, comparative, randomized, double-blind, placebo controlled clinical&#xD;
      trial with adaptive design. Females and males, aged 18 years and older, admitted to hospital&#xD;
      with severe COVID-19 pneumonia on SOC therapy will receive either levilimab 324 mg s/c or&#xD;
      placebo s/c. In case of no clinical improvement is observed, investigator can administer a&#xD;
      rescue therapy - open label LVL 324 mg s/c. The outcomes will be assessed up to day 60.&#xD;
      Results of interim analysis of safety and efficacy data of first 60 enrolled subjects will be&#xD;
      submitted for independent DMC review and decision about changes to the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Actual">August 3, 2020</completion_date>
  <primary_completion_date type="Actual">July 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with sustained clinical recovery</measure>
    <time_frame>Day 14</time_frame>
    <description>Sustained clinical recovery is defined as either an improvement of at least 2 categories relative to baseline on a 7-Category Ordinal Scale of Clinical Status or reaching categories &quot;Discharged&quot; / &quot;Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care&quot; at day 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reporting each category of 7-Category Ordinal Scale of Clinical Status</measure>
    <time_frame>Day 30</time_frame>
    <description>7-Category Ordinal Scale of Clinical Status:&#xD;
Not hospitalized / Discharged&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, requiring non-invasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients transferred to the ICU</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of fever</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ESR</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum CRP level</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum IL-6 level</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>LVL group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of levilimab at a dose of 324 mg in combination with standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single subcutaneous administration of placebo in combination with standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levilimab</intervention_name>
    <description>Levilimab 324 mg</description>
    <arm_group_label>LVL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent (subject; legally authorized representative) or signed&#xD;
             conclusion of panel of independent medical doctors&#xD;
&#xD;
          2. Males and non-pregnant females aged 18 years or older at the IC date&#xD;
&#xD;
          3. Positive test for SARS-CoV2 nucleic acid (RNA) at the IC date&#xD;
&#xD;
          4. Admitted as inpatient to a hospital with radiologically confirmed pneumonia&#xD;
&#xD;
          5. Severe form of COVID-19.&#xD;
&#xD;
          6. Subjects meeting any of the following criteria:&#xD;
&#xD;
               -  Total respiratory rate &gt; 30 breaths per minute&#xD;
&#xD;
               -  SpO2 ≤ 93%&#xD;
&#xD;
               -  PaO2 /FiO2 ≤ 300 mmHg&#xD;
&#xD;
               -  Chest imaging (X-ray, CT, US) showed lesion progression within 24-48 hours &gt;50%&#xD;
&#xD;
               -  Decrease of consciousness level, Psychomotor agitation/irritability&#xD;
&#xD;
               -  Hemodynamically unstable (systolic blood pressure &lt;90 mmHg or diastolic blood&#xD;
                  pressure &lt; 60 mmHg or urine output &lt; 20 ml/h)&#xD;
&#xD;
               -  Arterial lactate &gt; 2 mmol/l&#xD;
&#xD;
               -  qSOFA (quick sequential organ failure assessment score) &gt; 2. Subjects meeting&#xD;
                  three following criteria: Low blood pressure (SBP ≤ 100 mmHg); High respiratory&#xD;
                  rate (≥ 22 breaths/min); Altered mentation (Glasgow Coma Scale ≤ 14)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Critical COVID-19. Subjects meeting any of the following:&#xD;
&#xD;
               -  Respiratory failure and requiring invasive mechanical ventilation (tracheal&#xD;
                  intubation)&#xD;
&#xD;
               -  Septic shock&#xD;
&#xD;
               -  Multiple organ failure&#xD;
&#xD;
          2. Life expectancy &lt; 24h, in the opinion of the investigator,&#xD;
&#xD;
          3. Unlikely to remain at the investigational site beyond 48 hours&#xD;
&#xD;
          4. Use of other monoclonal antibodies for COVID-19 treatment&#xD;
&#xD;
          5. Current treatment with immunosuppressive agents (including corticosteroids)&#xD;
&#xD;
          6. Participating in other drug clinical trials at the IC date or within 60 days after&#xD;
             randomization (participation in COVID-19 anti-viral trials may be permitted if&#xD;
             approved by Sponsor)&#xD;
&#xD;
          7. Laboratory values:&#xD;
&#xD;
               -  ALT / AST &gt; 10 ULN at screening&#xD;
&#xD;
               -  Platelets &lt; 50х109/l at screening&#xD;
&#xD;
               -  Absolute Neutrophil Count &lt; 1х109/l at screening&#xD;
&#xD;
          8. Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)&#xD;
&#xD;
          9. Confirmed active tuberculosis&#xD;
&#xD;
         10. History of allergic reaction to monoclonal antibodies&#xD;
&#xD;
         11. Pregnancy or breastfeeding&#xD;
&#xD;
         12. Any illness or laboratory findings that, in the opinion of the study investigator,&#xD;
             might pose an additional risk to the patient by their participation in the study,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution Kaluga region &quot;Kaluga Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution of the Republic of Dagestan &quot;Republican Clinical Hospital&quot;</name>
      <address>
        <city>Machačkala</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.N. Bakulev National Medical Research Center of Cardiovascular Surgery</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 40 of the Department of Health of the city of Moscow</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No.52</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital № 15 named. O.M. Filatov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital №1 named after N.I. Pirogov, Moscow City Health Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Central Clinical Hospital with Clinic&quot;, Office of the President of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.M. Sechenov First Moscow State Medical University (Sechenov University)</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pirogov Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Railway clinical hospital named after N.A. Semashko</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Infectious Disease Hospital named after S.P. Botkin</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-western State Medical University named after I.I.Mechnikov</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Bashkir State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;North Ossetian State Medical Academy&quot; of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia)</name>
      <address>
        <city>Vladikavkaz</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

